Albireo Pharma

ALBO NASDAQ
23.43
+1.21
+5.45%
After Hours: 23.43 0 0.00% 17:00 08/16 EDT
Open
22.36
Prev Close
22.22
High
24.10
Low
22.36
Volume
30.94K
Avg Vol (3M)
58.64K
52 Week High
38.69
52 Week Low
19.10
% Turnover
0.24%
Market Cap
297.22M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Albireo Pharma ALBO stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. It is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI), disorders where improper flow or absorption of bile causes serious medical conditions for which there is unmet need. The target indication for its lead product candidate, A4250, is progressive familial intrahepatic cholestasis (PFIC), which is a genetic disorder affecting children. A4250 is being evaluated in a Phase II clinical trial. Other products in the Company's pipeline include Elobixibat, A3384 and Bile Acid Modulators. Elobixibat is indicated for the treatment of chronic constipation and it has completed its Phase III clinical trials. A3384 is a formulation of cholestyramine that is designed to release cholestyramine directly in the colon. It has completed a Phase II clinical trial of a prior formulation of A3384 in bile acid malabsorption (BAM).
MORE >

Recently

Name
Price
%Change